Shares of clinical-stage bio pharmaceutical company Altimmune, Inc. (ALT) are down more than 6% Thursday morning after the company said that the FDA has issued a clinical hold on the Investigational New Drug (IND) application for its Covid-19 vaccine candidate, AdCOVID.
The regulator asked the company for some protocol changes and also sought additional data on AdCOVID's chemistry, manufacturing and controls.
Altimmune said it has responded to the Agency's clinical hold letter received on December 22, 2020, does not see a significant impact on the overall clinical development timeline as the Company has agreed to each of the FDA's requests.
ALT, currently at $11.75, has been trading in the range of $1.60- $35.1 in the last one year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.